Deutsche Bank Ag\ Heron Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 59,786 shares of HRTX stock, worth $91,472. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,786

Previous 31,316 90.91%

Holding current value

$91,472

Previous $109,000 8.26%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.73 - $3.67 $49,253 - $104,484	28,470 Added 90.91%	59,786 $118,000
Q2 2024 Aug 14, 2024	SELL	$2.32 - $3.86 $29,113 - $48,439	-12,549 Reduced 28.61%	31,316 $109,000
Q1 2024 May 15, 2024	SELL	$1.71 - $3.06 $2,883 - $5,159	-1,686 Reduced 3.7%	43,865 $121,000
Q2 2023 Aug 14, 2023	SELL	$1.11 - $2.88 $23,962 - $62,173	-21,588 Reduced 32.15%	45,551 $52,000
Q1 2023 May 15, 2023	BUY	$1.51 - $3.25 $24,804 - $53,387	16,427 Added 32.39%	67,139 $101,000
Q4 2022 Feb 13, 2023	BUY	$2.25 - $4.67 $1,550 - $3,217	689 Added 1.38%	50,712 $126,000
Q3 2022 Nov 14, 2022	SELL	$2.66 - $5.37 $13,683 - $27,623	-5,144 Reduced 9.32%	50,023 $212,000
Q2 2022 Aug 11, 2022	SELL	$2.3 - $6.29 $319,534 - $873,857	-138,928 Reduced 71.58%	55,167 $154,000
Q1 2022 May 13, 2022	SELL	$4.63 - $9.94 $900,697 - $1.93 Million	-194,535 Reduced 50.06%	194,095 $1.11 Million
Q4 2021 Feb 11, 2022	SELL	$8.35 - $12.6 $1.17 Million - $1.77 Million	-140,710 Reduced 26.58%	388,630 $3.55 Million
Q3 2021 Nov 04, 2021	BUY	$10.13 - $15.0 $87,675 - $129,825	8,655 Added 1.66%	529,340 $5.66 Million
Q2 2021 Aug 11, 2021	BUY	$13.27 - $18.48 $1.35 Million - $1.89 Million	102,082 Added 24.39%	520,685 $8.08 Million
Q1 2021 May 13, 2021	SELL	$14.49 - $20.72 $3.95 Million - $5.65 Million	-272,725 Reduced 39.45%	418,603 $6.79 Million
Q4 2020 Feb 16, 2021	BUY	$14.61 - $22.14 $1.23 Million - $1.86 Million	84,027 Added 13.84%	691,328 $14.6 Million
Q3 2020 Nov 12, 2020	BUY	$13.67 - $17.77 $192,200 - $249,846	14,060 Added 2.37%	607,301 $9 Million
Q2 2020 Aug 13, 2020	BUY	$10.89 - $21.47 $1.88 Million - $3.7 Million	172,290 Added 40.93%	593,241 $8.73 Million
Q1 2020 May 14, 2020	SELL	$10.23 - $24.56 $1.05 Million - $2.51 Million	-102,361 Reduced 19.56%	420,951 $4.94 Million
Q4 2019 Feb 14, 2020	BUY	$17.42 - $26.61 $711,746 - $1.09 Million	40,858 Added 8.47%	523,312 $12.3 Million
Q3 2019 Nov 14, 2019	SELL	$16.36 - $21.39 $739,259 - $966,549	-45,187 Reduced 8.56%	482,454 $8.92 Million
Q2 2019 Aug 14, 2019	BUY	$16.93 - $26.22 $2.86 Million - $4.43 Million	168,971 Added 47.11%	527,641 $9.81 Million
Q1 2019 May 15, 2019	BUY	$23.15 - $28.34 $6.42 Million - $7.86 Million	277,263 Added 340.59%	358,670 $8.76 Million
Q4 2018 Feb 14, 2019	SELL	$22.03 - $32.01 $15.2 Million - $22.1 Million	-691,123 Reduced 89.46%	81,407 $2.11 Million
Q3 2018 Dec 21, 2021	BUY	$30.0 - $40.85 $14.1 Million - $19.2 Million	470,989 Added 156.19%	772,530 $24.5 Million
Q3 2018 Nov 14, 2018	SELL	$30.0 - $40.85 $19.3 Million - $26.2 Million	-642,394 Reduced 68.05%	301,541 $9.54 Million
Q2 2018 Apr 21, 2020	BUY	$26.4 - $42.0 $8.77 Million - $14 Million	332,196 Added 54.3%	943,935 $36.7 Million
Q2 2018 Aug 14, 2018	SELL	$26.4 - $42.0 $3.48 Million - $5.54 Million	-131,978 Reduced 17.75%	611,739 $23.8 Million
Q1 2018 Oct 18, 2019	BUY	$18.43 - $28.8 $4.68 Million - $7.32 Million	254,089 Added 51.89%	743,717 $20.5 Million
Q1 2018 May 15, 2018	BUY	$18.43 - $28.8 $898,757 - $1.4 Million	48,766 Added 11.06%	489,628 $13.5 Million
Q4 2017 Feb 14, 2018	BUY	$14.8 - $18.85 $582,172 - $741,483	39,336 Added 9.8%	440,862 $7.98 Million
Q3 2017 Nov 14, 2017	BUY	$14.65 - $16.85 $5.88 Million - $6.77 Million	401,526	401,526 $6.48 Million

Others Institutions Holding HRTX

# of Institutions

179

Shares Held

121M

Call Options Held

80.4K

Put Options Held

94.9K

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $182M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account